Abstract
Transarterial radioembolization (TARE) is a common technique to treat patients with hepatocellular carcinoma refractory to transarterial chemoembolization (TACE). TARE can cause liver toxicity. The degree of toxicity may be heightened due to previous liver injury from prior endovascular therapies. This study assessed the safety and changes in liver function after TARE for multifocal hepatocellular carcinoma refractory to previous embolization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.